AngioDynamics (ANGO) Misses Q2 EPS by 2c; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
AngioDynamics (ANGO) PT Lowered to $34 at Canaccord Genuity
January 7, 2022 7:21 AM ESTCanaccord Genuity analyst William Plovanic lowered the price target on AngioDynamics (NASDAQ: ANGO) to $34.00 (from $37.00) while maintaining a Buy rating following results and sector multiple compression.
The analyst commented, "ANGO reported FQ2/22 revenue of $78.3M (+7.6% Y/Y), beating our $77.7M estimate and consensus projection of $77.9M despite building a significant backlog due to manufacturing and shipping delays. ANGOs bottom line missed our... More
